戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ed salt and water intake in conjunction with fludrocortisone.
2 n a double-blinded fashion to receive either fludrocortisone 0.1 mg/day and salt 1 g/day or placebo t
3                      Mineralocorticoids (eg, fludrocortisone, 0.05-0.3 mg daily) should be added for
4 corticoid excess, MF1 mice were treated with fludrocortisone (16 weeks) but did not reproduce the fun
5 enous hydrocortisone 50 mg every 6 hours and fludrocortisone 50 mug daily had decreased mortality com
6 ure to a commonly prescribed corticosteroid, fludrocortisone acetate (FLU), at concentrations between
7 s with a similar steroid scaffold identified fludrocortisone acetate with both specific and highly po
8   Subjects were randomly assigned to receive fludrocortisone acetate, titrated to 0.1 mg/d (n = 50) o
9 e (24 mug/kg/h for 96 h), hydrocortisone and fludrocortisone alone, their respective combinations, or
10  0.53 for placebo versus hydrocortisone plus fludrocortisone and 0.64 for placebo versus hydrocortiso
11 2280 who began treatment with hydrocortisone-fludrocortisone and 85 995 (median [IQR] age, 67 [57-76]
12                 If symptoms are troublesome, Fludrocortisone and B-blockers remain the favored drugs.
13 ogical therapies are available and generally fludrocortisone and midodrine are the drugs of first cho
14    Symptoms recurred in 10 of 18 children on fludrocortisone and salt and in 5 of 14 children on plac
15 were similar in the 18 children treated with fludrocortisone and salt compared with the 14 children o
16          Intravascular volume expansion with fludrocortisone and salt has been reported to be effecti
17 cortisone at a 50 mg IV bolus every 6 hr and fludrocortisone as a 50 mug tablet once daily).
18             In our study of adults with CFS, fludrocortisone as monotherapy for NMH was no more effic
19 ure to identify symptomatic improvement with fludrocortisone does not disprove the hypothesis that NM
20 ith agents that increase central volume (eg, fludrocortisone, electrolyte-containing beverages), appe
21 reat analysis, 7 subjects (14%) treated with fludrocortisone experienced at least a 15-point improvem
22              (A randomised clinical trial of fludrocortisone for the prevention of vasovagal syncope;
23 y nonsignificant reduction in syncope in the fludrocortisone group (hazard ratio [HR]: 0.69: 95% conf
24 tion, there was a significant benefit due to fludrocortisone (HR: 0.51; 95% CI: 0.28 to 0.89; p = 0.0
25 ranking curve values for hydrocortisone plus fludrocortisone, hydrocortisone alone, and placebo were
26 dults with septic shock, hydrocortisone plus fludrocortisone improved short-term survival with minima
27 ble-blind trial that assessed the effects of fludrocortisone in vasovagal syncope over a 1-year treat
28 th an orally administered mineralocorticoid, fludrocortisone, increased TSC expression (656 +/- 114%
29 and examine the effects of calmidazolium and fludrocortisone-induced perturbation of primary human de
30 studied the effects of the mineralocorticoid fludrocortisone on the abundance of NCC and its phosphor
31                                  Addition of fludrocortisone on the same calendar day that hydrocorti
32  severity of orthostatic hypotension, use of fludrocortisone or compression garments, or diagnosis.
33 y and safety of hydrocortisone combined with fludrocortisone or hydrocortisone alone, compared with p
34                     Patients received either fludrocortisone or matching placebo at highest tolerated
35 l spells over a median of 9 years equally to fludrocortisone or placebo.
36  mortality at last follow-up was lowest with fludrocortisone plus hydrocortisone (RR, 0.85; 95% CrI,
37                            The comparison of fludrocortisone plus hydrocortisone versus hydrocortison
38 he scarcity of head-to-head trials comparing fludrocortisone plus hydrocortisone versus hydrocortison
39 usions: In adult patients with septic shock, fludrocortisone plus hydrocortisone was associated with
40                                              Fludrocortisone plus hydrocortisone was associated with
41  the comparative effectiveness and safety of fludrocortisone plus hydrocortisone, hydrocortisone alon
42   There is limited evidence whether being on fludrocortisone prevents vasovagal syncope.
43  its primary objective of demonstrating that fludrocortisone reduced the likelihood of vasovagal sync
44 s sought to determine whether treatment with fludrocortisone reduces the proportion of patients with
45                          Hydrocortisone plus fludrocortisone showed the lowest short-term mortality v
46                    In a multivariable model, fludrocortisone significantly reduced the likelihood of
47 aily urine samples in 25 patients undergoing fludrocortisone suppression testing (100 mug every 6 hou
48 ntroversial, and the effectiveness of adding fludrocortisone to hydrocortisone remains uncertain.
49 ht to evaluate the effectiveness of salt and fludrocortisone versus placebo in the prevention of sync
50 (47.2%) patients treated with hydrocortisone-fludrocortisone vs 43 669 (50.8%) treated with hydrocort
51 corticosteroid regimens (hydrocortisone with fludrocortisone vs hydrocortisone alone) is unclear.
52 an hydrocortisone treatment, the addition of fludrocortisone was superior to hydrocortisone alone.
53 r, treatment with the salt-retaining steroid fludrocortisone, which is usually beneficial in primary